GENERAL4 Sept 2026
Dadachanji Group launches Kaisha Pharma with 45-mn euros initial investment
Dadachanji Group launched Kaisha Pharma with 45 million euros initial investment. Kaisha Pharma will make ampoules, vials, prefilled syringes and cartridges. It targets Indian and global pharmaceutical and biotechnology companies. This spending is part of a bigger multi-million-euro plan to expand infrastructure, manufacturing capacity and operational capabilities. For businesses in the pharma supply chain, a new supplier is emerging. Watch for what Kaisha Pharma offers.
Key Statutory Highlights
- Dadachanji Group launched Kaisha Pharma with an initial investment of 45 million euros.
- Kaisha Pharma will manufacture ampoules, vials, prefilled syringes and cartridges.
- It will target Indian and global pharmaceutical and biotechnology companies, backed by a larger multi-million-euro investment commitment.
Actionable Advice for Taxpayers / Founders:Watch for Kaisha Pharma's entry into the market and evaluate whether its products suit your needs. Always confirm any new company's credentials before committing.
Statutory Disclaimer: TaxQue Shorts are AI-assisted editorial briefs for compliance awareness. This brief has not passed every source check; confirm the original notification before acting. This does not constitute formal legal or CA counsel.
TaxQue News Desk
Share: